Antithrombotic drug therapy in cardiovascular disease

Substantial morbidity and mortality remains associated with thrombotic eventshas stimulated the rapid expansion of the available armamentarium to combat pathologic thrombosis. Pathologic thrombosis plays an essential role in the pathogenesis of acute coronary syndromes (ACS), ischemic complications of percutaneous coronary intervention (PCI), venous thromboembolic disease, and embolic complications of arrhythmias and various cardiomyopathies. Written by experts in the field, Antithrombotic Drug Therapy in Cardiovascular Disease carefully examines individual and various combinations of the available antithrombotic regimens including fibrinolytic agents, antiplatelet therapies (aspirin, thieneopyridines, glycoprotein IIb/IIIa inhibitors), and anticogulant therapies (unfractionated heparin, low-molecular-weight heparins, direct thrombin inhibitors, and synthetic factor X inhibitors), non-ST-segment elevation (NSTE) ACS and ST-segment elevation myocardial infarction (STEMI). A detailed overview, Antithrombotic Drug Therapy in Cardiovascular Disease presents the evidence demonstrating the efficacy of available antithrombotic therapies in specific disease states such as atrial fibrillation, cardiomyopathy, valvular heart disease, and heparin-induced thrombocytopenia (HIT). INDICE: The Platelet in Arterial and Venous Thrombosis.- The Coagulation Cascade in Arterial and Venous Thrombosis.- The Link Between Thrombosis and Inflammation.- Genetics of Thrombosis.- Aspirin for Primary and Secondary Prevention.- Thienopyridines in Stable CAD Patients.- Anti-platelet Therapies: Aspirin, Thienopyridines, and Glycoprotein IIb/IIIa Inhibitors.- Unfractionated Heparin and Enoxaparin.- The Direct Thrombin Ihibitors.- Synthetic Factor Xa Inhibition, Fondaparinux.- Antiplatelet Therapies: Aspirin,Clopidogrel and thienopyridines and Glycoprotien IIb/IIIa Inhibitors.- Antithrombin Therapies: Unfractionated Heparin, Enoxaparin, Direct Thrombin Inhibitors, Fondaparinux.- Fibrinolysis and Facilitated PCI.- Antithrombotic Therapy in Percutaneous Coronary Intervention.- Antithrombotic Therapy in Carotid and Peripheral Intervention.- Monitoring of Antithrombotic Therapies.- Antithrombotic Therapy for DVT/PE.- Fibrinolysis for PE.- Duration of Anticoagulation Following VTE.-AntithromboticTherapy for Atrial Fibrillation.- Antithrombotic Therapy for Valvular Heart Disease.- Antithrombotic Therapy for Cardiomyopathy.- Heparin-Induced Thrombocytopenia.- 'Resistance' to Antiplatelet Therapies.

• ISBN: 978-1-60327-234-6
• Editorial: Humana
• Encuadernacion: Cartoné
• Páginas: 880
• Fecha Publicación: 01/10/2009
• Nº Volúmenes: 1
• Idioma: Inglés